Kura Oncology (KURA) CLO Teresa Brophy Sells 31,487 Shares

What Happened
Teresa Brophy, Chief Legal Officer of Kura Oncology (KURA), sold 31,487 shares in an open-market transaction on August 19, 2026, generating proceeds of approximately $397,681. The weighted average sale price was $12.63 per share; individual trade prices ranged from $12.44 to $12.83. This transaction is coded as a sale (S).

Key Details

• Transaction date: August 19, 2026; Form 4 filed August 21, 2026.
• Shares sold: 31,487; weighted average price: $12.63; total proceeds ≈ $397,681.
• Price range across multiple trades: $12.44–$12.83 (footnote F2). The filer offers to provide the exact breakdown of trades/prices on request.
• Source of shares: sold shares were acquired upon vesting of restricted stock units between Jan 26, 2024 and Jan 26, 2026 (footnote F1).
• Trading plan: sales were effected pursuant to a Rule 10b5-1 trading plan adopted May 20, 2026 (footnote F1).
• Shares owned after the transaction: not specified in the information provided in this filing.

Context
The shares sold came from previously vested RSUs and were sold under a pre-established 10b5-1 plan—common mechanisms insiders use for scheduled dispositions. Sales are typically routine liquidity events and, by themselves, do not necessarily indicate a change in the insider’s view of the company.